Jazz Pharmaceuticals plc has announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The study demonstrated that both investigational arms—Ziihera plus tislelizumab and chemotherapy, and Ziihera plus chemotherapy—resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared to trastuzumab plus chemotherapy, with approximately a 35% reduction in the risk of disease progression or death and a median progression-free survival of more than one year. These late-breaking results will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF57495) on January 06, 2026, and is solely responsible for the information contained therein.